pCAR-19B

ALL（3-21 pediatric）

2019.02

Filling the domestic gap: for the treatment of children and adolescents with relapsed/refractory B-cell acute lymphoblastic leukemia, the self-developed pCAR-19B autologous cell reinfusion preparation is the first CAR-T product in China to enter the phase II clinical stage for this indication. The overall response rate was 100%.

ALL（22-70 adult）

2020.05

Lymphoma

2020.05

C-4-29

Multiple myeloma for adults

2020.12

The first target in China: C-4-29 cell preparation with dual indications for both hematological tumors and solid tumors. It is the first CAR-T product targeting renal cell carcinoma solid tumors in China. Both indications have obtained the registered clinical implied license.

Renal cell carcinoma for adults

2021.09

C-13-60

advanced malignant solid tumors that progress or are intolerant after systematic standard treatment and have no effective treatment means

2022.12

The first CAR-T product targeting CEA approved by clinical trials in China. Its second indication ：the unique intraperitoneal local medication can break through the limitations of traditional intravenous infusion, establish a long-lasting circulating immunity, enhance the killing of solid tumors and prevent recurrence, and may reduce the risk caused by off-target effect.

This candidate product is indicated for patients ≥ 18 years of age with CEA-positive advanced malignancies，including colorectal cancer, esophageal cancer, gastric cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, bile duct cancer, etc.

2023.12

MC-1-50

For patients (≥ 18 years of age) with relapsed/refractory CD19-positive B-cell non-Hodgkin's lymphoma

2023.10

It is a CD19-targeted CAR-T cell product based on the company's innovative PRIMCAR ® platform, which implements a new faster and more efficient CAR-T preparation technology that results in lower doses, fewer side effects, and longer lasting effects.

For patients ≥ 18 years of age with relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia

2023.12